Table 2.
Pathway enrichment analysis of aberrantly-DEGs in HCC
| Pathway ID | Term | Count | P value |
|---|---|---|---|
| Hypomethylation and high expression | |||
| hsa04110 | Cell cycle | 8 | 4.3E-4 |
| hsa00040 | Pentose and glucuronate interconversions | 4 | 7.3E-3 |
| hsa00240 | Pyrimidine metabolism | 5 | 2.8E-2 |
| hsa04114 | Oocyte meiosis | 5 | 3.3E-2 |
| hsa04115 | p53 signaling pathway | 4 | 3.8E-2 |
| Hypermethylation and high expression | |||
| hsa05204 | Chemical carcinogenesis | 5 | 4.1E-3 |
| hsa04022 | cGMP-PKG signaling pathway | 6 | 1.2E-2 |
| hsa04080 | Neuroactive ligand-receptor interaction | 7 | 2.6E-2 |
| hsa04916 | Melanogenesis | 4 | 4.9E-2 |
| hsa04930 | Type II diabetes mellitus | 3 | 5.9E-2 |